36 days ago by evalsweet

New Research In The Treatment Of Cancer Of Immune System. New enquiry provides more demonstrate that treating incontestable lymphoma patients with an overpriced analgesic over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantl ...

Eva Sweet - evalsweet.blogspot.com

46 days ago by Danielle Tipton

I hope that everyone had a wonderful Christmas, Chanukah, or whatever you celebrate! We have been very blessed this year. My kids had probably one of the best Christmas' ever. We made some great memories with family, had some great meals, we watched a historical documentary of the birth of Christ, a ...

My 10 yr old is an old ... - emilysarthritisfight.blogspot.com · 1 reference

65 days ago by John Carroll

Biogen Idec CEO George Scangos ( photo) has made good on his vow to hammer out a major joint venture on biosimilars. The biotech has announced it is joining forces with South Korean conglomerate Samsung, biting off $45 million of a $300 million investment to ramp up a new operation to develop, manuf ...

FierceBiotech - fiercebiotech.com/news/frontpage · Rank: 53,988 · 72 references

66 days ago by Tracy Staton

Genentech joins the whistleblower-settlement crowd, albeit with a payment dwarfed by most of the pharma industry's False Claims Act deals. As the San Francisco Business Times reports, the Roche unit agreed to pay $20 million to wrap up the suit, which claimed that the company marketed Rituxan for of ...

FiercePharma - fiercepharma.com/news/frontpage · Rank: 83,098

69 days ago by Ed Silverman

The Swiss drugmaker’s Genentech unit has agreed to pay $20 million to settle a whistleblower lawsuit brought by a former sales manager, who alleged that the Rituxan immunosupressant was marketed off-label and that the promotional activities caused the federal healthcare programs, including Medicare ...

Pharmalot - pharmalot.com · Rank: 2,621 · 708 references

86 days ago by sheliakroll

New Research In The Treatment Of Cancer Of Immune System. New scrutinize provides more data that treating predestined lymphoma patients with an high-priced numb over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly enhance ...

Shelia Kroll - sheliakroll.blogspot.com

90 days ago by DrWei

(Video: Watch this video on the post page) Rituxan Combined With a TNF Inhibitor and Methotrexate Safe But Not Any More Effective For RA ScienceDaily reports a recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumat ...

Arthritis Treatment Center ... - arthritistreatmentcenter.com/blog

93 days ago by The Wheelchair Kamikaze

Image by Images_of_Money via Flickr The mix of money and medicine often makes for a strange brew. Far too often, conflicts arise between what is best for the patient and what is best for the bottom line. Over the last several decades, treating chronic illness has mushroomed into a worldwide multibil ...

Wheelchair Kamikaze - wheelchairkamikaze.com · Rank: 53,326 · 48 references

93 days ago by alanadumais

New Research In The Treatment Of Cancer Of Immune System. New inquire into provides more witness that treating steady lymphoma patients with an up-market stupefy over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly enhance ...

Alana Dumais - alanadumais.blogspot.com

110 days ago by Michel Silvestri

Nja, det är nog definitivt för tidigt att påstå att vi nu har både orsak och optimal behandling fastställd för sjukdomstillståndet ME/CFS. Icke desto mindre så är det mycket intressanta signaler som kommer från studier utförda av doktorerna Fluge och Mella vid Haukeland Universitetssjukhus i Norge. ...

Pesto Silvestri - pestosilvestri.blogspot.com · Rank: 136,326 · 5 references